In this issue of Current Oncology

In women with early-stage breast cancer, the use of fec-d (5-fluorouracil–epirubicin–cyclophosphamide followed by docetaxel) has increased, given the increased efficacy of that regimen compared with fec-100 (5-fluorouracil–epirubicin–cyclophosphamide).[...]